Published in BMC Gastroenterol on December 24, 2009
TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals (Basel) (2012) 1.02
Genetics of human gastrointestinal sensation. Neurogastroenterol Motil (2013) 0.79
Prevalence of pain-related single nucleotide polymorphisms in patients of African origin with sickle cell disease. Pharmacogenomics (2015) 0.75
Transient receptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats with chronic pancreatitis. Gastroenterology (2007) 1.44
Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain (2006) 1.30
Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut (2002) 1.29
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut (2005) 1.20
Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol (2006) 1.16
The role of Transient Receptor Potential Vanilloid 1 (TRPV1) channels in pancreatitis. Biochim Biophys Acta (2007) 1.14
Pharmacological management of pain in chronic pancreatitis. Dig Liver Dis (2006) 1.13
Survey on chronic pancreatitis in the Asia-Pacific region. J Gastroenterol Hepatol (2004) 1.12
Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol. Neuropharmacology (2009) 1.08
Review article: pain and chronic pancreatitis. Aliment Pharmacol Ther (2009) 1.07
Pharmacologic disruption of TRPV1-expressing primary sensory neurons but not genetic deletion of TRPV1 protects mice against pancreatitis. Pancreas (2008) 1.02
Transient receptor potential vanilloid (TRPV-1) promotes neurogenic inflammation in the pancreas via activation of the neurokinin-1 receptor (NK-1R). Pancreas (2005) 1.00
Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. Am J Physiol Renal Physiol (2007) 0.97
Does the pain-protective GTP cyclohydrolase haplotype significantly alter the pattern or severity of pain in humans with chronic pancreatitis? Mol Pain (2008) 0.95
Local disruption of the celiac ganglion inhibits substance P release and ameliorates caerulein-induced pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol (2006) 0.95
The genomic organization of the gene encoding the vanilloid receptor: evidence for multiple splice variants. Genomics (2001) 0.94
Chronic pancreatitis. Curr Opin Gastroenterol (2008) 0.85
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2004) 6.06
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol (2011) 3.53
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol (2004) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A (2010) 1.79
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol (2013) 1.79
Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet (2003) 1.77
Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med (2003) 1.76
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
Short mucin 6 alleles are associated with H pylori infection. World J Gastroenterol (2006) 1.67
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology (2011) 1.58
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol (2005) 1.41
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2008) 1.35
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci (2009) 1.34
Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain (2011) 1.32
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30
Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med (2004) 1.29
Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med (2005) 1.28
2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol (2005) 1.26
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25
Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.24
Pragmatic trials in primary care. Methodological challenges and solutions demonstrated by the DIAMOND-study. BMC Med Res Methodol (2007) 1.24
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther (2004) 1.23
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology (2007) 1.12
Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11
Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease. Hum Mutat (2006) 1.10
Proliferation of authors on research reports in medicine. Sci Eng Ethics (1996) 1.09
Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain (2011) 1.09
[Quality indicators for colonoscopy: differences in polyp detection between endoscopists at one hospital]. Ned Tijdschr Geneeskd (2012) 1.08
Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. J Hepatol (2009) 1.06
Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int (2009) 1.05
Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol (2005) 1.04
Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. Brain (2010) 1.04
Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscul Disord (2008) 1.03
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer (2009) 1.03
HCV treatment--no more room for interferonologists? N Engl J Med (2013) 1.03
Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood (2006) 1.02
Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int (2011) 1.02
Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol (2011) 1.01
Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci U S A (2014) 1.00
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol (2013) 0.99
Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg (2007) 0.98
Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart (2012) 0.98
Functional dyspepsia: not all roads seem to lead to rome. J Clin Gastroenterol (2009) 0.96
High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk. Int J Oncol (2012) 0.95
GWAS-uncovered SNPs in PLCE1 and RFT2 genes are not implicated in Dutch esophageal adenocarcinoma and squamous cell carcinoma etiology. Eur J Cancer Prev (2013) 0.95
Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol (2007) 0.93
FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging (2004) 0.93
Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol (2009) 0.93
Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons. Nat Rev Neurol (2010) 0.93
Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease. Gastroenterology (2004) 0.93
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol (2010) 0.92
Familial Mediterranean fever--a not so unusual cause of abdominal pain. Best Pract Res Clin Gastroenterol (2005) 0.92
Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer (2011) 0.91
Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer (2013) 0.91
Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med (Berl) (2006) 0.91
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int (2007) 0.91
Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction? J Hepatol (2008) 0.90
A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med (2003) 0.90
Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population. Oncol Res (2010) 0.90